نتائج البحث - "Ted Gooley"

الوصف: Cord blood transplantation (CBT) can cure life-threatening blood disorders. The HLA-B leader affects the success of unrelated donor transplantation but its role in CBT is unknown. We tested the hypothesis that the HLA-B leader influences CBT outcomes in unrelated single-unit cord blood transplants performed by Eurocord/European Blood and Marrow Transplant (EBMT) centers between 1990 and 2018 with data reported to Eurocord. Among 4,822 transplants, 2,178 had one HLA-B mismatch of which 1,013 were HLAA and HLA-A and -DRB1 matched. The leader (methionine [M] or threonine [T]) was determined for each HLA-B allele in patients and units to define the genotype. Among single HLA-B-mismatched transplants, the patient/unit mismatched alleles were defined as leader-matched if they encoded the same leader, or leader-mismatched if they encoded different leaders; the leader encoded by the matched (shared) allele was determined. The risks of graft-versus-host disease, relapse, non-relapse mortality and overall mortality were estimated for various leader-defined groups using multi-variable regression models. Among the 1,013 HLA-A and -DRB1-matched transplants with one HLA-B mismatch, increasing numbers of cord blood unit M-leader alleles was associated with increased risk of relapse (hazard ratio [HR] for each increase in one Mleader allele 1.30, 95% Confidence Interval [CI]: 1.05-1.60, P=0.02). Furthermore, leader mismatching together with an M-leader of the shared HLA-B allele lowered non-relapse mortality (HR 0.44, 95% CI: 0.23-0.81; P=0.009) relative to leader matching and a shared T-leader allele. The HLA-B leader may inform relapse and non-relapse mortality risk after CBT. Future patients might benefit from the appropriate selection of units that consider the leader.

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/10073Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/1b247e14d33f43df8055c490cf61c897Test

View record in DOAJ

النص الكامل

3

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms

المؤلفون: Noam E. Kopmar, Ted Gooley, Niall Curley, Kathryn Russell, Carole Shaw, Kelda Schonhoff, John Lim, Anna B. Halpern, Roland B. Walter, Bart L. Scott, Jacob Appelbaum, Paul C. Hendrie, Elihu H. Estey, Mary-Elizabeth M. Percival

المصدر: Leukemia & Lymphoma. :1-3

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::558049d9b65bf08addd097a1b15c395dTest
https://doi.org/10.1080/10428194.2023.2185087Test

4

The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and treatment

المؤلفون: Anisha Naik, Ted Gooley, Keith Loeb, Lorinda Soma, Stephen D. Smith, Ajay Gopal, Kikkeri N. Naresh

المصدر: British Journal of Haematology. 199:696-706

مصطلحات موضوعية: Databases, Factual, Humans, Hematology, Prognosis, Rituximab, Lymphoma, Follicular

الوصف: Currently, there is no convincing evidence that the grade of follicular lymphoma (FL) impacts patient outcome. We correlated grades in 33 925 patients with nodal FL during 1992-2018 in the SEER database with disease-specific survival (DSS) and overall survival (OS). Patients with FL grade 3 had lower DSS and OS as compared to FL grades 1-2. During 1992-2005, the 10-year DSS for patients with FL grades 3 and grades 1-2 were 68.6%, and 71.4%, respectively, and in 2006-2018, they were 77.7% and 82.6%, respectively. The 10-year OS estimates in 1992-2005 were 49.9% and 54.2% for grade 3 and grades 1-2 respectively, and in 2006-2018, they were 59.1% and 63.5% for grade 3 and grades 1-2, respectively. After adjustment for stage and age, the hazard ratios for death due to FL and death from any cause for patients with FL grade 3 during 1992-2005 were 1.09 (1.02-1.16) and 1.07 (1.02-1.12), respectively, compared to FL grades 1-2; and during 2006-2018, the hazard ratios for death due to FL and death from any cause for patients with FL grade 3 were 1.34 (1.22-1.45) and 1.16 (1.10-1.23), respectively compared to FL grades 1-2. The grade of FL is an important determinant of disease biology.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2f52ddb5ab21520e601ab83e9416babTest
https://doi.org/10.1111/bjh.18404Test

5

Supplementary Figures 1 - 3 from Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I

المؤلفون: Paul Nghiem, Cassian Yee, David M. Koelle, Cindy Desmarais, Ted Gooley, Kendall C. Shibuya, Shailender Bhatia, Heather L. Sloan, Ilana M. Roberts, Ivy Lai, Joo Ha Hwang, Upendra Parvathaneni, Kelly G. Paulson, Jayasri G. Iyer, Olga K. Afanasiev, Aude G. Chapuis

الوصف: PDF file - 738K, Supplementary Fig. S1: Detection of MCPyV-specific CD8 T cells among tumor infiltrating lymphocytes (TIL) from the primary MCC tumor (left) and PBMC (right). Cells were stained with A24/MCPyV.LT.92-101 tetramer and CD8. Supplementary Fig. S2: A) Cell products destined for infusions 1, 2 and 3 bound the MCPyV LT-Ag92-101 peptide-HLA tetramer. B) Products secreted IFNγ (left) and lysed MCPyV LT-Ag92-101 -pulsed FUJI (A24+ cell line) and autologous PBMC pulsed with 10?g/ml peptide (right). The product used for infusion 1 is shown and is representative. Supplementary Fig. S3: Assessment of CD25hiCD127loCD4+ T-cells in PBMC collected at baseline (137 days and immediately prior to the first treatment) and at indicated timepoints after treatments. Gray bars on x-axis indicate the timing of each treatment as detailed in Figure 1.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6db7e984993205f4f853e71a39c28e16Test
https://doi.org/10.1158/2326-6066.22535900.v1Test

6

Data from Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I

المؤلفون: Paul Nghiem, Cassian Yee, David M. Koelle, Cindy Desmarais, Ted Gooley, Kendall C. Shibuya, Shailender Bhatia, Heather L. Sloan, Ilana M. Roberts, Ivy Lai, Joo Ha Hwang, Upendra Parvathaneni, Kelly G. Paulson, Jayasri G. Iyer, Olga K. Afanasiev, Aude G. Chapuis

الوصف: Merkel cell carcinoma (MCC) is an aggressive skin cancer that typically requires the persistent expression of Merkel cell polyomavirus (MCPyV) oncoproteins that can serve as ideal immunotherapeutic targets. Several immune evasion mechanisms are active in MCC, including downregulation of HLA class-I expression on tumor cells and dysfunctional endogenous MCPyV-specific CD8 T-cell responses. To overcome these obstacles, we combined local and systemic immune therapies in a 67-year-old man, who developed metastatic MCPyV-expressing MCC. Intralesional IFN-β-1b or targeted single-dose radiation was administered as a preconditioning strategy to reverse the downregulation of HLA-I expression noted in his tumors and to facilitate the subsequent recognition of tumor cells by T cells. This was followed by the adoptive transfer of ex vivo expanded polyclonal, polyomavirus-specific T cells as a source of reactive antitumor immunity. The combined regimen was well tolerated and led to persistent upregulation of HLA-I expression in the tumor and a durable complete response in two of three metastatic lesions. Relative to historical controls, the patient experienced a prolonged period without development of additional distant metastases (535 days compared with historic median of 200 days; 95% confidence interval, 154–260 days). The transferred CD8+ T cells preferentially accumulated in the tumor tissue, remained detectable and functional for more than 200 days, persisted with an effector phenotype, and exhibited evidence of recent in vivo activation and proliferation. The combination of local and systemic immune stimulatory therapies was well tolerated and may be a promising approach to overcome immune evasion in virus-driven cancers. Cancer Immunol Res; 2(1); 27–36. ©2013 AACR.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f31668861506a1e7777cf2fede8524bcTest
https://doi.org/10.1158/2326-6066.c.6547979.v1Test

7

The impact of B‐cell‐directed therapy on SARS‐CoV ‐2 vaccine efficacy in chronic lymphocytic leukaemia

المصدر: British Journal of Haematology. 197:306-309

مصطلحات موضوعية: COVID-19 Vaccines, SARS-CoV-2, COVID-19, Humans, Vaccine Efficacy, Hematology, Leukemia, Lymphocytic, Chronic, B-Cell

الوصف: Prior reports evaluating SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia (CLL) used semiquantitative measurements of anti-S to evaluate immunity; however, neutralization assays were used to assess functional immunity in the trials leading to vaccine approval. Here, we identified decreased rates of seroconversion in vaccinated CLL patients and lower anti-S levels compared to healthy controls. Notably, we demonstrated similar results with the Roche anti-S assay and neutralization activity. Durable responses were seen at six months; augmentation with boosters was possible in responding patients. Absence of normal B cells, frequently seen in patients receiving Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors, was a strong predictor of lack of seroconversion.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c788df2d9d1a0acffca9c58e70a0bc2Test
https://doi.org/10.1111/bjh.18088Test

8

Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

المؤلفون: Darrell R. Fisher, Ryan D. Cassaday, David G. Maloney, Ted Gooley, Damian J. Green, Sherilyn A. Tuazon, Stephen D. Smith, Victor A. Chow, Manuela Matesan, Brenda M. Sandmaier, Oliver W. Press, Johnnie J. Orozco, Ajay K. Gopal

المصدر: Blood Advances

الوصف: Key Points Megadose radioimmunotherapy with 90Y-ibritumomab tiuxetan treats relapsed/refractory aggressive BCLs safely and successfully.Radioimmunotherapy conditioning regimens warrant further exploration for curative-intent treatment in relapsed/refractory lymphomas.
Visual Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative for relapsed or refractory B-cell lymphomas (BCLs), although outcomes are worse in aggressive disease, and most patients will still experience relapse. Radioimmunotherapy using 90Y-ibritumomab tiuxetan can induce disease control across lymphoma subtypes in a dose-dependent fashion. We hypothesized that megadoses of 90Y-ibritumomab tiuxetan with reduced-intensity conditioning could safely produce deeper remissions in aggressive BCL further maintained with the immunologic effect of allo-HCT. In this phase 2 study, CD20+ BCL patients received outpatient 90Y-ibritumomab tiuxetan (1.5 mCi/kg; maximum, 120 mCi), fludarabine, and then 2 Gy total body irradiation before HLA-matched allo-HCT. Twenty patients were enrolled after a median of 4.5 prior lines of therapy, including 14 with prior autologous transplant and 4 with prior anti-CD19 chimeric T-cellular therapy. A median 90Y-ibritumomab tiuxetan activity of 113.6 mCi (range, 71.2-129.2 mCi) was administered, delivering a median of 552 cGy to the liver (range, 499-2411 cGy). The estimated 1- and 5-year progression-free survival was 55% (95% confidence interval [CI], 31-73) and 50% (95% CI, 27-69) with a median progression-free survival of 1.57 years. The estimated 1- and 5-year overall survival was 80% (95% CI, 54-92) and 63% (95% CI, 38-81) with a median overall survival of 6.45 years. Sixteen patients (80%) experienced grade 3 or higher toxicities, although nonrelapse mortality was 10% at 1 year. No patients developed secondary acute myeloid leukemia/myelodysplastic syndrome. Megadose 90Y-ibritumomab tiuxetan, fludarabine, and low-dose total body irradiation followed by an HLA-matched allo-HCT was feasible, safe, and effective in treating aggressive BCL, exceeding the prespecified end point while producing nonhematologic toxicities comparable to those of standard reduced-intensity conditioning regimens.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486da9ccd0510a9ad572571d3f4ac8b4Test
http://europepmc.org/articles/PMC8753215Test

9

Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin

المؤلفون: Ted Gooley, Barry E. Storer, Frederick R. Appelbaum, Mohamed L. Sorror, Albert C. Yeh, Jason P. Cooper, Kris Doney, Paul O'Donnell, Paul J. Martin, Jeannine S. McCune, H. Joachim Deeg, Gary Schoch, Mary E.D. Flowers, C. McFarland

المصدر: Bone Marrow Transplant

الوصف: We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days), fludarabine (Flu, 120 [n=23] or 250 [n=17] mg/m(2)) and thymoglobulin (THY). Compared to 95 patients conditioned with Bu/Cyclophosphamide (Cy) without THY, BuFluTHY-conditioned patients had lower rates of chronic graft-vs.-host disease (GVHD). Adjusted hazard ratios (HR) for BuFlu(120)THY and BuFlu(250)THY-conditioned patients were 1.60 (95% confidence interval (CI) 0.66 to 3.86) and 1.87 (0.68 to 5.11), respectively, for relapse; 0.77 (0.30 to 1.99) and 1.32 (0.54 to 3.23) for non-relapse mortality; 0.81 (0.42 to 1.57) and 1.38 (0.72 to 2.57) for overall mortality; and 0.78 (0.30 to 2.05) and 1.62 (0.63 to 4.41) for relapse or death (failure for relapse-free survival). At one year, 45% of BuFlu(120 or 250)THY conditioned patients had mixed CD3+ chimerism compared to 0% with BuCy (p

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::080635b00c643b790145caa5a697a5c5Test
https://doi.org/10.1038/s41409-021-01518-0Test

10

Two Biologic-Assignment Studies Evaluating the Efficacy of Hematopoietic Cell Transplant Among Older Patients With High-Risk Myelodysplastic Syndrome

المؤلفون: Ted Gooley

المصدر: Journal of Clinical Oncology. 39:3311-3314

مصطلحات موضوعية: Oncology, Biological Products, Cancer Research, medicine.medical_specialty, Transplantation Conditioning, Hematopoietic cell, business.industry, Hematopoietic Stem Cell Transplantation, MEDLINE, Older patients, Myelodysplastic Syndromes, Internal medicine, Humans, Medicine, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8b473767375ef79b3a41d7deca1594aTest
https://doi.org/10.1200/jco.21.01594Test

تنقيح النتائج